// App-Quantinova.ai

EP465 : UPDATED PHARMACODYNAMIC AND SURVIVAL OUTCOMES FROM THE AG221-AML-005 TRIAL OF ENASIDENIB (ENA) PLUS AZACITIDINE (AZA) IN PATIENTS WITH MUTANT IDH2 NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (ND-AML)

Researchers

Presenter

  • Courtney DiNardo

Principal Investigators

  • Andre Schuh

  • Eytan Stein

  • Pau Montesinos

  • Andrew Wei

  • Stphane de Botton

  • Amer Zeidan

  • Amir Fathi

  • Hagop Kantarjian

  • Patricia Martin-Regueira

  • Frederik Lersch

  • Hina Maniar

  • Jing Gong

  • Paresh Vyas

  • Hartmut Dhner

Medical Centers

  • The Alfred Hospital, Melbourne, Australia

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Hospital Universitari I Politecnic La Fe, Valencia, Spain

  • Deakin University, Melbourne, Australia

  • Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA

  • Universitatsklinikum Ulm, Ulm, Germany

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • Gustave Roussy, Villejuif, France

  • Bristol Meyers Squibb,Princeton,United States

  • NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford

  • Yale School of Medicine, New Haven, Connecticut, United States

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

Locations

  • Australia

  • Canada

  • Spain

  • United States

  • Germany

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • Isocitrate dehydrogenase 2

Drug/Treatment

  • Vidaza

  • Enasidenib

  • AG221

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved